Advanced Enzyme Technologies Limited

NSE: ADVENZYMES · Healthcare

₹280.30-1.41%06 Nov 2026

Ask the data

Instant answers about Advanced Enzyme Technologies Limited — computed from its filings, no language model

Market cap₹3,091 cr

Current price₹280.30

High / Low₹392 / ₹248

P/E18.1

P/B1.86

Book value₹151.0

ROE10.3%

ROCE14.4%

Debt / equity0.01

Dividend yield1.93%

EPS (TTM)₹15.50

Face value₹2

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	395.7	419.6	444.0	501.8	529.4	540.6	623.9	636.9	745.8
EBITDA	164.0	181.9	202.3	231.5	201.4	156.4	204.5	194.4	229.1
Operating margin	41.4%	43.4%	45.6%	46.1%	38.0%	28.9%	32.8%	30.5%	30.7%
Interest	8.1	3.9	3.0	1.6	1.8	2.4	2.9	3.6	2.6
Depreciation	18.3	21.1	25.8	28.4	35.0	35.0	35.2	36.6	40.1
Profit before tax	139.0	162.0	179.2	210.4	171.1	140.4	187.8	187.4	232.5
Tax	45.4	46.1	46.1	58.9	47.3	36.5	50.9	53.4	58.9
Net profit	90.1	111.1	129.3	146.2	119.6	105.6	133.3	131.1	168.7
EPS ₹	8.07	9.95	11.58	13.09	10.70	9.45	11.92	11.72	15.08
Operating cash flow	—	—	—	—	123.5	140.4	141.4	142.5	156.8
Capex	—	—	—	—	28.2	38.2	42.4	34.8	52.4
Dividend paid	—	—	—	—	0.0	12.5	56.7	59.0	59.8
Total assets	—	—	—	—	—	1,421.8	1,535.5	1,621.3	1,838.8
Equity	—	—	—	—	—	1,235.1	1,324.1	1,420.9	1,632.0

Quarterly performance

last 35 quarters · ₹ crore

showing latest 8 of 35 periods

	MAR '18	JUN '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	108.6	104.3	103.2	101.7	110.4	110.3	111.4	111.9	110.3	110.5	120.4	137.7	133.2	137.0	127.1	133.6	131.7	121.1	138.7	142.1	138.7	147.3	157.8	160.9	157.8	154.5	146.1	169.1	167.2	185.9	184.5	171.9	203.4	189.8	214.5
Operating profit	48.4	48.4	42.1	41.7	49.7	53.5	47.3	52.9	48.7	51.7	58.5	66.4	54.9	62.8	49.3	49.0	40.3	30.9	39.7	41.7	44.1	44.0	51.3	53.8	55.4	51.2	42.4	55.2	45.6	56.4	60.0	49.4	63.2	51.0	72.1
Operating margin	44.6%	46.4%	40.8%	41.0%	45.0%	48.5%	42.4%	47.2%	44.2%	46.8%	48.6%	48.2%	41.2%	45.8%	38.8%	36.7%	30.6%	25.5%	28.6%	29.3%	31.8%	29.9%	32.5%	33.4%	35.1%	33.1%	29.0%	32.7%	27.3%	30.4%	32.5%	28.7%	31.1%	26.9%	33.6%
Other income	0.6	0.4	2.0	0.0	2.6	1.1	1.5	1.2	1.8	5.2	0.6	1.4	1.7	0.9	0.9	1.2	3.4	2.0	3.9	8.5	11.1	6.7	6.1	14.4	9.5	7.0	9.6	7.7	8.7	8.8	10.3	8.5	7.2	13.0	8.7
Interest	4.5	1.4	2.3	-0.3	0.6	0.8	0.7	0.8	0.7	0.5	0.4	0.3	0.4	0.5	0.3	0.3	0.7	0.6	0.6	0.6	0.6	0.7	0.8	0.7	0.8	0.9	0.9	0.9	0.8	0.8	0.7	0.6	0.6	0.6	1.2
Depreciation	4.7	5.2	5.2	5.4	5.3	6.3	6.5	6.4	6.7	6.7	6.8	6.5	8.4	8.3	8.6	8.8	9.1	8.6	8.8	9.1	8.4	8.6	8.7	8.6	9.3	8.6	8.9	9.0	10.1	9.6	10.1	10.2	10.2	9.9	10.9
Profit before tax	39.8	42.2	36.6	36.7	46.5	47.5	41.6	46.9	43.2	49.8	51.9	60.9	47.8	54.9	41.2	41.1	34.0	23.7	34.1	40.5	42.1	41.4	47.9	58.9	39.6	48.7	42.2	53.0	43.5	54.9	59.5	58.3	59.8	53.5	68.8
Tax	11.4	10.9	10.8	11.3	13.0	13.5	9.8	12.3	10.5	15.0	13.3	16.6	14.0	15.1	11.0	12.6	8.7	6.1	7.9	12.5	10.0	12.0	12.7	16.4	9.7	13.7	8.8	14.1	16.7	14.5	14.8	15.1	14.6	14.9	17.6
Net profit	27.2	29.7	24.7	24.4	32.2	33.4	30.9	33.6	31.3	34.2	38.6	43.1	31.7	38.0	30.3	27.5	24.4	17.9	26.2	29.4	32.1	28.8	34.4	41.8	28.3	34.1	32.8	37.6	26.5	39.9	43.3	42.5	43.0	37.1	48.3
EPS ₹	2.44	2.66	2.21	2.19	2.89	2.99	2.77	3.01	2.81	3.07	3.33	3.86	2.84	3.40	2.66	2.46	2.19	1.60	2.34	2.63	2.87	2.58	3.08	3.74	2.53	3.05	2.94	3.36	2.37	3.57	3.87	3.80	3.84	3.31	4.33
Revenue YoY	—	—	—	—	1.6%	5.8%	8.0%	10.0%	-0.1%	0.1%	8.0%	23.0%	20.8%	24.0%	5.6%	-3.0%	-1.1%	-11.6%	9.1%	6.4%	5.3%	21.6%	13.8%	13.3%	13.8%	4.9%	-7.4%	5.1%	5.9%	20.3%	26.3%	1.7%	21.6%	2.1%	16.2%
Profit YoY	—	—	—	—	18.2%	12.6%	25.2%	37.4%	-2.7%	2.5%	24.6%	28.2%	1.1%	11.1%	-21.5%	-36.2%	-22.9%	-53.0%	-13.4%	7.1%	31.5%	61.2%	31.3%	41.9%	-11.9%	18.5%	-4.6%	-9.9%	-6.5%	16.9%	32.0%	12.9%	62.2%	-7.1%	11.5%

Earlier results (standalone, Sep '16 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Advanced Enzyme Technologies Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Quarters

	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	41.2	41.6	53.6	48.3	49.2	58.0
Operating profit	13.6	11.4	14.4	9.6	7.4	13.5
Operating margin	33.1%	27.4%	26.8%	19.8%	15.0%	23.2%
Other income	1.1	1.1	2.4	0.2	2.4	1.6
Interest	0.5	0.6	0.6	0.7	0.9	0.7
Depreciation	2.1	2.1	1.8	1.9	1.9	2.0
Profit before tax	12.2	9.8	14.5	7.1	6.9	12.4
Tax	2.8	1.8	2.0	2.0	1.5	2.4
Net profit	9.3	8.0	12.5	5.1	5.4	10.0
EPS ₹	4.26	3.61	5.65	0.46	0.48	0.90
Revenue YoY	—	—	—	—	19.3%	39.4%
Profit YoY	—	—	—	—	-42.1%	25.6%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 32 periods

	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	8.2%	8.4%	8.6%	9.4%	10.0%	11.0%	10.1%	10.5%	10.2%	9.9%	9.2%	9.6%	9.9%	10.3%	10.3%	10.2%	10.3%
ROCE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	11.5%	11.4%	11.4%	12.9%	13.8%	15.2%	14.1%	14.7%	14.1%	13.7%	13.2%	13.7%	14.2%	14.6%	14.2%	14.1%	14.4%
Net margin	25.4%	26.5%	27.0%	27.9%	29.3%	29.1%	29.3%	30.4%	30.7%	29.4%	28.6%	26.7%	24.0%	22.7%	19.5%	18.3%	18.4%	19.5%	20.6%	21.3%	22.7%	21.4%	22.0%	22.1%	21.2%	20.6%	20.5%	20.9%	21.5%	22.6%	22.1%	21.9%
EBITDA margin	43.2%	43.4%	43.9%	44.3%	45.8%	45.6%	45.2%	46.7%	47.1%	46.1%	45.9%	43.6%	40.7%	38.1%	33.0%	30.5%	28.6%	28.9%	29.9%	30.9%	32.0%	32.8%	33.5%	32.7%	32.5%	30.5%	29.9%	30.8%	29.8%	30.7%	29.8%	30.2%
Debt / equity	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.01	0.01	0.01	0.01	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.01	0.01
Interest coverage	20.93	42.85	51.53	97.75	63.69	60.32	68.97	83.31	111.05	131.66	134.86	132.31	120.39	96.13	73.92	61.97	54.32	59.25	64.75	66.36	71.75	65.11	62.93	57.87	52.12	53.78	57.28	66.30	76.59	89.75	95.74	83.89
Asset turnover	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.39	0.39	0.38	0.40	0.41	0.42	0.41	0.41	0.40	0.41	0.39	0.41	0.42	0.42	0.41	0.41	0.41

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 9 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	22.4	22.4	22.4	22.4	22.4	22.4	22.4	22.4	22.1
Other equity / reserves	1,141.8	1,212.7	1,225.9	1,301.8	1,319.3	1,398.5	1,462.2	1,609.6	1,642.7
Total equity	1,164.2	1,235.1	1,248.3	1,324.1	1,341.7	1,420.9	1,484.5	1,632.0	1,664.8
Borrowings	14.4	13.2	20.7	25.1	25.7	21.5	19.6	20.5	21.8
Current liabilities	72.6	77.6	87.4	106.4	104.0	96.8	106.7	106.7	117.1
Non-current liabilities	64.9	60.1	57.8	58.0	56.4	55.9	51.6	48.9	68.8
Total assets	1,353.2	1,421.8	1,443.9	1,535.5	1,549.2	1,621.3	1,691.9	1,838.8	1,905.7
Property, plant & equipment	262.3	273.2	273.4	276.5	281.1	292.9	284.4	275.8	307.7
Capital work-in-progress	15.8	15.6	16.5	30.7	33.9	21.7	31.0	51.2	83.2
Investments	234.5	359.7	342.0	403.0	395.9	480.3	529.3	583.9	488.3
Inventories	123.5	124.0	135.6	148.5	168.4	157.3	173.4	177.3	202.7
Receivables	100.5	100.3	112.0	98.6	98.8	115.4	125.3	145.0	138.0
Cash & equivalents	174.9	96.4	99.9	113.8	97.8	94.2	62.4	108.8	158.8

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY25	FY26
Cash from operations	123.5	140.4	141.4	142.5	156.8
Cash from investing	-26.1	-298.2	-64.7	-89.1	-74.1
Cash from financing	-27.4	-25.8	-59.2	-72.5	-70.4
Capex	28.2	38.2	42.4	34.8	52.4
Free cash flow	95.3	102.2	99.0	107.7	104.4
Dividends paid	0.0	12.5	56.7	59.0	59.8

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹307.7 cr16%

CWIP

₹83.2 cr4%

Investments

₹488.3 cr26%

Inventories

₹202.7 cr11%

Receivables

₹138.0 cr7%

Cash & equivalents

₹158.8 cr8%

Other assets

₹527.0 cr28%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Advanced Enzyme Technologies Limited	3,091	280.30	18.1	1.86	10.3%

StoxGud checklist: Neutral setup · 6/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+3.8%

6 months-22.1%

1 year-9.3%

3Y CAGR-4.2%

5Y CAGR-4.8%

10Y CAGR-3.0%

50-day avg₹280.20

200-day avg₹308.68

RSI (14)59

FAQs

What is the share price of Advanced Enzyme Technologies Limited?

Advanced Enzyme Technologies Limited (ADVENZYMES) closed at ₹280.30 on NSE on 06 Nov 2026.

What is the market cap of Advanced Enzyme Technologies Limited?

₹3,091 crore at the latest close.

What is the P/E ratio of Advanced Enzyme Technologies Limited?

18.1, on trailing-twelve-month earnings from its filings.

How fast is Advanced Enzyme Technologies Limited growing?

Advanced Enzyme Technologies Limited: revenue has compounded at 11.3% a year over three years; net profit at 16.9% a year. Latest-quarter revenue is up 16.2% year on year, profit up 11.5%.

How profitable is Advanced Enzyme Technologies Limited?

On a trailing-twelve-month basis return on equity is 10.3%, return on capital employed 14.4%, operating margin 30.2%, net margin 21.9%.

How much debt does Advanced Enzyme Technologies Limited have?

Advanced Enzyme Technologies Limited is debt-free: debt to equity is 0.01 with borrowings of ₹22 cr against cash of ₹159 cr (balance sheet of 2026-09-30). Operating profit covers interest 83.9 times.

Financials parsed from Advanced Enzyme Technologies Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.